Oncostat

Group leader
Stefan Michiels

Contact
Tel : + 33 (0)1 42 11 41 44
E-mail

Bâtiment de médecine moléculaire,
Niveau 0, pièce 85

Frise Banner: 
Oncostat

Publications

  • Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart MJ, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. J Clin Oncol. 2019 Jan 16:JCO1801010.
  • Bayar MA, Le Teuff G, Koenig F, Le Deley MC, Michiels S. Group sequential adaptive designs in series of time-to-event randomised trials in rare diseases: A simulation study. Stat Methods Med Res. 2019 Jul 29:962280219862313.
  • Lacas B, Bourhis J, Overgaard J, Zhang Q, Grégoire V, Nankivell M, Zackrisson B, Szutkowski Z, Suwinski R, Poulsen M, O'Sullivan B, Corvo R, Laskar SG, Fallai C, Yamazaki H, Dobrowsky W, Cho KH, Beadle B, Langendijk JA, Viegas CMP, Hay J, Lotayef M, Parmar MKB, Aupérin A, van Herpen C, Maingon P, Trotti AM, Grau C, Pignon JP, Blanchard P; MARCH Collaborative Group. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol. 2017 Sep;18(9):1221-1237.
  • Salgado R, Moore H, Martens JWM, Lively T, Malik S, McDermott U, Michiels S, Moscow JA, Tejpar S, McKee T, Lacombe D; IBCD-Faculty. Steps forward for cancer precision medicine. Nat Rev Drug Discov. 2018 Jan;17(1):1-2
  • Ternès N, Rotolo F, Michiels S. biospear: an R package for biomarker selection in penalized Cox regression. Bioinformatics. 2018 Jan 1;34(1):112-113.
  • Devarakonda S, Rotolo F, Tsao MS, Lanc I, Brambilla E, Masood A, Olaussen KA, Fulton R, Sakashita S, McLeer-Florin A, Ding K, Le Teuff G, Shepherd FA, Pignon JP, Graziano SL, Kratzke R, Soria JC, Seymour L, Govindan R, Michiels S. Tumor Mutation Burden as Biomarker in Resected Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 Oct 20;36(30):2995-3006.
  • Rotolo F, Paoletti X, Burzykowski T, Buyse M, Michiels S. A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses. Stat Methods Med Res. 2017 Jan 1:962280217718582.
  • Lacas B, Bourhis J, Overgaard J, Zhang Q, Grégoire V, Nankivell M, Zackrisson B, Szutkowski Z, Suwiński R, Poulsen M, O'Sullivan B, Corvò R, Laskar SG, Fallai C, Yamazaki H, Dobrowsky W, Cho KH, Beadle B, Langendijk JA, Viegas CMP, Hay J, Lotayef M, Parmar MKB, Aupérin A, van Herpen C, Maingon P, Trotti AM, Grau C, Pignon JP, Blanchard P; MARCH Collaborative Group. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol. 2017 Sep;18(9):1221-1237.
  • Lueza B, Rotolo F, Bonastre J, Pignon JP, Michiels S. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis. BMC Med Res Methodol. 2016;16:37.  
  • Borget I, Bonastre J, Catargi B, Déandréis D, Zerdoud S, Rusu D, Bardet S, Leenhardt L, Bastie D, Schvartz C, Vera P, Morel O, Benisvy D, Bournaud C, Bonichon F, Kelly A, Toubert ME, Leboulleux S, Journeau F, Benhamou E, Schlumberger M. Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase III ESTIMABL Trial. J Clin Oncol. 2015 Sep 10;33(26):2885-92.
Catégorie de la page: